New EU Filings
Vutrisiran, Alnylam’s investigational RNAi therapeutic for treating hereditary transthyretin-mediated amyloidosis in adults with polyneuropathy, is among the latest new medicines that have been submitted for review for potential pan-EU approval.
You may also be interested in...
The European Medicines Agency has added seven new products to its list of medicines that are under review for potential EU marketing authorization.
The European Medicines Agency has added nine new products to its latest list of medicines that are under review for potential EU marketing authorization.
The European Patent Office has adjusted the starting date of its transitional measures for applicants that want their patent to have unitary effect under the coming Unified Patent Court system.